Printer Friendly

NCCN Announces Important Updates to Pancreatic Adenocarcinoma Clinical Practice Guidelines.

JENKINTOWN, Pa. -- The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Pancreatic Adenocarcinoma Guidelines. The NCCN Clinical Practice Guidelines in Oncology(TM) are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated continually and are based upon evaluation of scientific data integrated with expert judgment.

A randomized study in 533 patients with advanced or metastatic pancreatic cancer found that overall survival and objective response rates were significantly improved in patients receiving gemcitabine (Gemzar, Eli Lilly) plus capecitabine (Xeloda, Roche) when compared to gemcitabine alone. A phase III trial of erlotinib (Tarceva, Genentech) plus gemcitabine versus gemcitabine alone demonstrated a median survival of 6.4 months and a 1-year survival of 24% in the erlotinib arm, as compared with 5.9 months and 17% in the control arm. Based upon a review of this information, the panel added the combination therapy options of gemcitabine plus capecitabine and gemcitabine plus erlotinib. The combinations were added as recommendations in the adjuvant setting and in the management of locally advanced unresectable and metastatic disease.

"NCCN Guidelines highlight the cutting-edge developments in treatment and are an essential tool for physicians, allied health professionals, patients and public and private payors," said William T. McGivney, Ph.D., Chief Executive Officer of the NCCN.

For a detailed listing of all updates to the NCCN Guidelines, please go to

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN member institutions are: City of Hope Cancer Center, Los Angeles, CA; Dana-Farber/Partners CancerCare, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Hospital & Clinics, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The University of Nebraska Medical Center, Omaha, NE; and The University of Texas M. D. Anderson Cancer Center, Houston, TX.

For more information, visit
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 13, 2006
Previous Article:Department of Education to Disallow In-School Student Loan Consolidations.
Next Article:Fitch Rates Oregon's $12MM GO Alternate Energy Bonds 'AA-'; Stable Outlook.

Related Articles
"J. of the National Comprehensive Cancer Network" from Jones and Bartlett.
MEDINET, Yokohama City University, Shin-Yokohama Medical Clinic Jointly Launch Clinical Study of Immune Cell Therapy for Pancreatic Cancer.
NCCN Announces Important Updates to Cancer- and Treatment-Related Anemia Guidelines.
NCCN Announces Important Updates to Soft Tissue Sarcoma Guidelines.
Avantogen Oncology Inc. Announces FDA Acceptance Of Its IND For The Novel Cancer Drug Candidate, RP101.
Avantogen Oncology Inc. Files IND Application for RP101.
NCCN Updates Thyroid Carcinoma Guidelines.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters